Orexo, a specialty pharmaceutical company, engages in the development and commercialization of drugs. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. The Company's development projects comprise OX382, oral formulation of buprenorphine; OX-CLI, a novel treatment of respiratory disorders, such as asthma and COPD; OX-MPI, for inflammatory related pain; and OX51, a sublingual formulation containing alfentanil for the prevention of acute pain during short surgical and diagnostic procedures.
Market capitalization (6-Aug-2020)
Closing stock price (6-Aug-2020)
Orexo has 462 Twitter Followers. The number of followers has increased 2.1% month over month and increased 12.6% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Orexo founded?
Orexo was founded in 1995.
Who are Orexo key executives?
Orexo's key executives are Robert A. DeLuca, James Noble and Staffan Lindstrand.
How many employees does Orexo have?
Orexo has 136 employees.
Who are Orexo competitors?
Competitors of Orexo include Sunshine Biopharma, Pharco Pharmaceuticals and Sanfer.
Where is Orexo headquarters?
Orexo headquarters is located at 7E Rapsgatan, Uppsala.
Where are Orexo offices?
Orexo has offices in Uppsala and Morristown.
How many offices does Orexo have?
Orexo has 2 offices.
Receive alerts for 300+ data fields across thousands of companies